<p>Van ECK Associates Corp 在最近向证券交易委员会的披露中表示，在第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股减少了 49.7%。该公司在季度内出售了 708,792 股后，持有 716,087 股这家医疗器械供应商的股票。Van ECK Associates Corp 在最近一个季度末持有西氏医药服务 1.00% 的股份，价值为 197,025,000 美元。</p>
<ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
<p>其他机构投资者也对该公司的持仓进行了调整。Holocene Advisors LP 在第三季度新购入了价值 49,085,000 美元的西氏医药服务股份。Nordea Investment Management AB 在第四季度将其在西氏医药服务的持仓提高了 42.7%。Nordea Investment Management AB 目前持有 14,950 股这家医疗器械供应商的股票，价值为 4,122,000 美元，此前在上个季度又购买了 4,477 股。摩根大通在第三季度将其在西氏医药服务的持仓提高了 7.7%。摩根大通目前持有 236,963 股这家医疗器械供应商的股票，价值为 62,163,000 美元，此前在上个季度又收购了 16,919 股。Birch Hill Investment Advisors LLC 在第四季度将其在西氏医药服务的持仓提高了 11.5%。Birch Hill Investment Advisors LLC 目前持有 152,148 股这家医疗器械供应商的股票，价值为 41,862,000 美元，此前在上个季度又收购了 15,678 股。最后，DAVENPORT &amp; Co LLC 在第四季度将其在西氏医药服务的持仓提高了 559.8%。DAVENPORT &amp; Co LLC 目前持有 9,521 股这家医疗器械供应商的股票，价值为 2,620,000 美元，此前在上个季度又收购了 8,078 股。93.90% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>WST 最近成为几份分析师报告的主题。Evercore 在 4 月 24 日的报告中重申了对西氏医药服务的 “跑赢大盘” 评级。Wolfe Research 在 6 月 1 日的报告中开始覆盖西氏医药服务的股票。他们对该股票设定了 “跑赢大盘” 评级和 375.00 美元的目标价。巴克莱在周二的报告中将西氏医药服务的评级从 “持平” 上调至 “增持”，并将其目标价从 310.00 美元提高至 400.00 美元。Zacks Research 在 5 月 13 日的报告中将西氏医药服务的评级从 “持有” 上调至 “强烈买入”。最后，Weiss Ratings 在 4 月 27 日的研究报告中将西氏医药服务的评级从 “持有（c-）” 上调至 “持有（c）”。两位研究分析师给予该股票 “强烈买入” 评级，十位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，平均目标价为 340.09 美元。</p>
<ul>
<li>今年将推动 S&amp;P 500 表现的因素是什么？</li>
</ul>
<p><strong>查看我们对 WST 的最新分析</strong></p>
<h2>西氏医药服务股票表现</h2>
<p>NYSE:WST 周五开盘价为 328.33 美元。西氏医药服务公司过去 12 个月的最低价为 206.80 美元，最高价为 336.82 美元。该公司的流动比率为 2.71，速动比率为 2.04，债务与股本比率为 0.07。该公司的 50 日移动平均线为 298.97 美元，200 日移动平均线为 271.63 美元。该公司的市值为 232 亿美元，市盈率为 43.89，市盈增长比率为 2.76，贝塔值为 1.18。</p>
<ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
<p>西氏医药服务（NYSE:WST - 获取免费报告）在 4 月 23 日星期四发布了季度财报。这家医疗器械供应商报告本季度每股收益为 2.13 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.45 美元。西氏医药服务的净利润率为 16.85%，股本回报率为 19.03%。该公司本季度的收入为 8.449 亿美元，而分析师预期为 7.7968 亿美元。去年同期，该公司的每股收益为 1.45 美元。该公司本季度的收入同比增长 21.0%。西氏医药服务已将其 2026 财年的指引设定为每股收益 8.400-8.750 美元，2026 年第二季度的指引为每股收益 2.050-2.120 美元。分析师预测西氏医药服务公司在当前财年将发布每股收益 8.6 美元。</p>
<p>西氏医药服务宣布其董事会已于 2 月 17 日授权了一项股票回购计划，允许公司回购价值 10 亿美元的流通股。该回购授权允许这家医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
<h2>内部活动</h2>
<p>在其他西氏医药服务的新闻中，副总裁安妮特·F·费沃瑞特于 4 月 27 日星期一出售了 2,817 股该公司的股票。股票以平均价格 305.20 美元出售，总价值为 859,748.40 美元。交易完成后，副总裁直接持有该公司 16,828 股股票，价值 5,135,905.60 美元。这笔交易代表了他们持股比例的 14.34% 的减少。该出售在向 SEC 的文件中披露，相关信息可通过此链接获取。此外，首席会计官查德·温特斯于 4 月 27 日星期一出售了 896 股该公司的股票。股票以平均价格 300.67 美元出售，总交易额为 269,400.32 美元。交易完成后，首席会计官持有 1,523 股公司的股票，价值约 457,920.41 美元。这笔交易代表了他们持股比例的 37.04% 的减少。该出售的 SEC 文件提供了更多信息。公司内部人士持有公司股票的 0.60%。</p>
<h2>西氏医药服务公司简介</h2>
<p>（免费报告）</p>
<p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西氏以其保持无菌性和与敏感药物配方兼容的弹性密封件、密封圈和聚合物组件而闻名。</p>
<p>除了组件制造，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过西氏医药服务</li>
<li>TJX：零售业的顶级掠食者在通货膨胀中大快朵颐</li>
<li>MarketBeat 周回顾 – 06/08 - 06/12</li>
<li>SpaceX 敲响钟声，打破所有记录</li>
<li>Adobe 股票刚刚变得更便宜——华尔街是否忽视了这个故事？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
<p>在考虑西氏医药服务之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而西氏医药服务并不在名单上。</p>
<p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

西氏医药服务

摩根大通

JPMO

<p>Van ECK Associates Corp 在第四季度将其对西氏医药服务（WST）的持股减少了 49.7%，目前保留 716,087 股，价值 1.97 亿美元。其他机构如 Nordea 和摩根大通则增加了他们的持股。分析师们维持了一致的 “买入” 评级，平均目标价为 340.09 美元。WST 最近公布了强劲的第一季度财报，收益超出预期，每股收益为 2.13 美元，营收为 8.449 亿美元，同比增长 21%</p>

<p>Van ECK Associates Corp reduced its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST - Free Report) by 49.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 716,087 shares of the medical instruments supplier's stock after selling 708,792 shares during the quarter. Van ECK Associates Corp owned 1.00% of West Pharmaceutical Services worth $197,025,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Van ECK Associates Corp 在最近向证券交易委员会的披露中表示，在第四季度将其在西氏医药服务公司（NYSE:WST - 免费报告）的持股减少了 49.7%。该公司在季度内出售了 708,792 股后，持有 716,087 股这家医疗器械供应商的股票。Van ECK Associates Corp 在最近一个季度末持有西氏医药服务 1.00% 的股份，价值为 197,025,000 美元。</p>
</div><ul>
<li>3 Dividend Champions with room for dividend growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只有潜力增加股息的股息冠军</li>
</ul>
</div><p>Other institutional investors have also made changes to their positions in the company. Holocene Advisors LP acquired a new position in shares of West Pharmaceutical Services during the third quarter worth $49,085,000. Nordea Investment Management AB lifted its position in shares of West Pharmaceutical Services by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 14,950 shares of the medical instruments supplier's stock worth $4,122,000 after purchasing an additional 4,477 shares in the last quarter. JPMorgan Chase &amp; Co. raised its holdings in West Pharmaceutical Services by 7.7% in the third quarter. JPMorgan Chase &amp; Co. now owns 236,963 shares of the medical instruments supplier's stock valued at $62,163,000 after acquiring an additional 16,919 shares in the last quarter. Birch Hill Investment Advisors LLC raised its holdings in West Pharmaceutical Services by 11.5% in the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier's stock valued at $41,862,000 after acquiring an additional 15,678 shares in the last quarter. Finally, DAVENPORT &amp; Co LLC raised its holdings in West Pharmaceutical Services by 559.8% in the fourth quarter. DAVENPORT &amp; Co LLC now owns 9,521 shares of the medical instruments supplier's stock valued at $2,620,000 after acquiring an additional 8,078 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者也对该公司的持仓进行了调整。Holocene Advisors LP 在第三季度新购入了价值 49,085,000 美元的西氏医药服务股份。Nordea Investment Management AB 在第四季度将其在西氏医药服务的持仓提高了 42.7%。Nordea Investment Management AB 目前持有 14,950 股这家医疗器械供应商的股票，价值为 4,122,000 美元，此前在上个季度又购买了 4,477 股。摩根大通在第三季度将其在西氏医药服务的持仓提高了 7.7%。摩根大通目前持有 236,963 股这家医疗器械供应商的股票，价值为 62,163,000 美元，此前在上个季度又收购了 16,919 股。Birch Hill Investment Advisors LLC 在第四季度将其在西氏医药服务的持仓提高了 11.5%。Birch Hill Investment Advisors LLC 目前持有 152,148 股这家医疗器械供应商的股票，价值为 41,862,000 美元，此前在上个季度又收购了 15,678 股。最后，DAVENPORT &amp; Co LLC 在第四季度将其在西氏医药服务的持仓提高了 559.8%。DAVENPORT &amp; Co LLC 目前持有 9,521 股这家医疗器械供应商的股票，价值为 2,620,000 美元，此前在上个季度又收购了 8,078 股。93.90% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>WST has been the topic of several recent analyst reports. Evercore reaffirmed an &#34;outperform&#34; rating on shares of West Pharmaceutical Services in a report on Friday, April 24th. Wolfe Research assumed coverage on shares of West Pharmaceutical Services in a report on Monday, June 1st. They set an &#34;outperform&#34; rating and a $375.00 target price on the stock. Barclays raised shares of West Pharmaceutical Services from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and increased their target price for the stock from $310.00 to $400.00 in a report on Tuesday. Zacks Research raised shares of West Pharmaceutical Services from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Wednesday, May 13th. Finally, Weiss Ratings upgraded shares of West Pharmaceutical Services from a &#34;hold (c-)&#34; rating to a &#34;hold (c)&#34; rating in a research report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Buy&#34; and an average price target of $340.09.</p>
<div class="lb-trans"><p>WST 最近成为几份分析师报告的主题。Evercore 在 4 月 24 日的报告中重申了对西氏医药服务的 “跑赢大盘” 评级。Wolfe Research 在 6 月 1 日的报告中开始覆盖西氏医药服务的股票。他们对该股票设定了 “跑赢大盘” 评级和 375.00 美元的目标价。巴克莱在周二的报告中将西氏医药服务的评级从 “持平” 上调至 “增持”，并将其目标价从 310.00 美元提高至 400.00 美元。Zacks Research 在 5 月 13 日的报告中将西氏医药服务的评级从 “持有” 上调至 “强烈买入”。最后，Weiss Ratings 在 4 月 27 日的研究报告中将西氏医药服务的评级从 “持有（c-）” 上调至 “持有（c）”。两位研究分析师给予该股票 “强烈买入” 评级，十位分析师给予 “买入” 评级，两位分析师给予 “持有” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “买入”，平均目标价为 340.09 美元。</p>
</div><ul>
<li>What Factors Will Drive S&amp;P 500 Performance This Year?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年将推动 S&amp;P 500 表现的因素是什么？</li>
</ul>
</div><p><strong>Check Out Our Latest Analysis on WST</strong></p>
<div class="lb-trans"><p><strong>查看我们对 WST 的最新分析</strong></p>
</div><h2>West Pharmaceutical Services Stock Performance</h2>
<div class="lb-trans"><h2>西氏医药服务股票表现</h2>
</div><p>NYSE:WST opened at $328.33 on Friday. West Pharmaceutical Services, Inc. has a twelve month low of $206.80 and a twelve month high of $336.82. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07. The company has a 50-day moving average of $298.97 and a 200-day moving average of $271.63. The firm has a market cap of $23.20 billion, a price-to-earnings ratio of 43.89, a price-to-earnings-growth ratio of 2.76 and a beta of 1.18.</p>
<div class="lb-trans"><p>NYSE:WST 周五开盘价为 328.33 美元。西氏医药服务公司过去 12 个月的最低价为 206.80 美元，最高价为 336.82 美元。该公司的流动比率为 2.71，速动比率为 2.04，债务与股本比率为 0.07。该公司的 50 日移动平均线为 298.97 美元，200 日移动平均线为 271.63 美元。该公司的市值为 232 亿美元，市盈率为 43.89，市盈增长比率为 2.76，贝塔值为 1.18。</p>
</div><ul>
<li>Healthcare Stocks With at Least 30 Years of Dividend Increases</li>
</ul>
<div class="lb-trans"><ul>
<li>至少有 30 年股息增长的医疗保健股票</li>
</ul>
</div><p>West Pharmaceutical Services (NYSE:WST - Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The company had revenue of $844.90 million during the quarter, compared to analyst estimates of $779.68 million. During the same quarter last year, the firm posted $1.45 EPS. The business's revenue for the quarter was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>西氏医药服务（NYSE:WST - 获取免费报告）在 4 月 23 日星期四发布了季度财报。这家医疗器械供应商报告本季度每股收益为 2.13 美元，超出市场共识预期的 1.68 美元，超出幅度为 0.45 美元。西氏医药服务的净利润率为 16.85%，股本回报率为 19.03%。该公司本季度的收入为 8.449 亿美元，而分析师预期为 7.7968 亿美元。去年同期，该公司的每股收益为 1.45 美元。该公司本季度的收入同比增长 21.0%。西氏医药服务已将其 2026 财年的指引设定为每股收益 8.400-8.750 美元，2026 年第二季度的指引为每股收益 2.050-2.120 美元。分析师预测西氏医药服务公司在当前财年将发布每股收益 8.6 美元。</p>
</div><p>West Pharmaceutical Services declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, February 17th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 5.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.</p>
<div class="lb-trans"><p>西氏医药服务宣布其董事会已于 2 月 17 日授权了一项股票回购计划，允许公司回购价值 10 亿美元的流通股。该回购授权允许这家医疗器械供应商通过公开市场购买最多 5.6% 的股份。股票回购计划通常表明公司的董事会认为其股票被低估。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other West Pharmaceutical Services news, VP Annette F. Favorite sold 2,817 shares of the firm's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president directly owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Chad Winters sold 896 shares of the firm's stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company's stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company's stock.</p>
<div class="lb-trans"><p>在其他西氏医药服务的新闻中，副总裁安妮特·F·费沃瑞特于 4 月 27 日星期一出售了 2,817 股该公司的股票。股票以平均价格 305.20 美元出售，总价值为 859,748.40 美元。交易完成后，副总裁直接持有该公司 16,828 股股票，价值 5,135,905.60 美元。这笔交易代表了他们持股比例的 14.34% 的减少。该出售在向 SEC 的文件中披露，相关信息可通过此链接获取。此外，首席会计官查德·温特斯于 4 月 27 日星期一出售了 896 股该公司的股票。股票以平均价格 300.67 美元出售，总交易额为 269,400.32 美元。交易完成后，首席会计官持有 1,523 股公司的股票，价值约 457,920.41 美元。这笔交易代表了他们持股比例的 37.04% 的减少。该出售的 SEC 文件提供了更多信息。公司内部人士持有公司股票的 0.60%。</p>
</div><h2>West Pharmaceutical Services Company Profile</h2>
<div class="lb-trans"><h2>西氏医药服务公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.</p>
<div class="lb-trans"><p>西氏医药服务公司是一家全球开发和制造组件、系统及服务的公司，旨在实现可注射药物的封装和输送。该公司专注于为制药和生物技术行业提供高质量的包装和输送解决方案，生产用于疫苗、生物制剂和其他可注射疗法的主要药物包装组件和专用药物输送设备。西氏以其保持无菌性和与敏感药物配方兼容的弹性密封件、密封圈和聚合物组件而闻名。</p>
</div><p>In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.</p>
<div class="lb-trans"><p>除了组件制造，西氏还提供工程化输送系统和产品生命周期支持服务。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than West Pharmaceutical Services</li>
<li>TJX: Retail’s Apex Predator Feasts on Inflation</li>
<li>MarketBeat Week in Review – 06/08 - 06/12</li>
<li>SpaceX Rings the Bell and Shatters Every Record</li>
<li>Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过西氏医药服务</li>
<li>TJX：零售业的顶级掠食者在通货膨胀中大快朵颐</li>
<li>MarketBeat 周回顾 – 06/08 - 06/12</li>
<li>SpaceX 敲响钟声，打破所有记录</li>
<li>Adobe 股票刚刚变得更便宜——华尔街是否忽视了这个故事？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVdTVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=WST"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in West Pharmaceutical Services Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在西氏医药服务吗？</h2>
</div><p>Before you consider West Pharmaceutical Services, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑西氏医药服务之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and West Pharmaceutical Services wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而西氏医药服务并不在名单上。</p>
</div><p>While West Pharmaceutical Services currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然西氏医药服务目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Van ECK Associates Corp Decreases Stock Holdings in West Pharmaceutical Services, Inc. $WST

Market Beat

YieldMax JPM Option Income Strategy ETF

Defiance Daily Target 2X Long JPM ETF

诺底亚银行(ADR)

Evercore

巴克莱银行

标普 500 指数

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Van ECK Associates Corp 减少了其在西氏医药服务公司（West Pharmaceutical Services, Inc.）的股票持有量 $WST